Echo IQ (ASX:EIQ) said the usage of EchoSolv AS, its decision support software for the assessment of severe aortic stenosis, a progressive heart condition, was up around 131% quarter over quarter in the three months ended March 31, according to a Thursday Australian bourse filing.

The company said 9,220 echocardiograms were processed in the first quarter, from 3,992 in the December 2025 quarter.

The company is progressing its heart failure clinical decision support product, EchoSolv HF, through the US Food and Drug Administration 510(k) pathway.

It is also focused on securing major US hospital group signings and advancing regulatory clearance via Australia's Therapeutic Goods Administration, per the filing.

Echo IQ's shares fell nearly 2% in recent trading on Thursday.